Company

Spruce Biosciences, Inc.

Headquarters: Daly City, CA, United States

Employees: 19

CEO: Dr. Javier Szwarcberg M.D., M.P.H.

NASDAQ: SPRB +3.49%

Market Cap

$119.7 Million

USD as of Jan. 1, 2024

Market Cap History

Spruce Biosciences, Inc. market capitalization over time

Evolution of Spruce Biosciences, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Spruce Biosciences, Inc.

Detailed Description

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Spruce Biosciences, Inc. has the following listings and related stock indices.


Stock: NASDAQ: SPRB wb_incandescent

Details

Headquarters:

2001 Junipero Serra Boulevard

Suite 640

Daly City, CA 94014

United States

Phone: 415-294-1687